News

33A is an antibody-drug conjugate (ADC) targeted to CD33 utilizing Seattle Genetics’ newest technology, comprising an engineered cysteine antibody (EC-mAb) stably linked to a highly potent DNA binding

The unrestricted grants will be awarded to organizations with a track record of excellence in results-driven research. Gilead Sciences executive vice president of research William Lee said: "For

ViiV Healthcare CEO Dominique Limet said: "As a result of these transactions, ViiV Healthcare now has one of the most robust HIV pipelines in the industry. "The assets

Under the terms of the deal, Unilife grants Amgen exclusive rights to its wearable injectors within select drug classes for use with certain Amgen drugs. Amgen will also

The sNDA includes findings from the phase 2 Terrain and Strive studies, to update the appropriate clinical sections within the existing indication. The FDA approved enzalutamide to treat

The phase 3 ONCEMRK study, which is assessing Isentress in earlier untreated HIV-1 infected adults, met its primary efficacy endpoint by demonstrating that 1200mg of Isentress once-daily was

This announcement furthers the Company’s previously announced actions on October 22, 2015 to maximize efficiency and continue leveraging the strength of Perrigo’s global platform. A number of positions

Epilepsy is a brain disorder that causes people to have recurring seizures. A seizure is an episode, usually of relatively short duration, of abnormal brain activity. Seizures can

The FDA has extended the date for agency action by the standard period, from Feb. 27, 2016 to May 27, 2016. Following the Psychopharmacologic Advisory Committee meeting in